第３３回生命医科学セミナーBiomedical Science Seminar）
演 題：Targeting oncogenic mutant p53 for cancer therapy
(がん遺伝子としての変異p53 ― そのメカニズムとがん分子標的治療への応用)
演 者：Dr. Tomoo Iwakuma（岩熊 智雄 博士）
Department of Cancer Biology,
University of Kansas Medical Center
日 時：平成２６年７月２８日（月） １８：００～１９：００
場 所：病院地区総合研究棟１階１０４セミナー室
Mutations in the tumor suppressor p53, which are detected in more than 50% of human tumors, result in not only loss of function as a transcription factor, but also gain of oncogenic activities (gain of function: GOF). Our recent findings suggest that mutant p53 is inherently unstable in normal tissues but get stabilized in tumors, leading to induction of the GOF activity. Intriguingly, downregulation of mutant p53 in cancer cells significantly reduces their malignant properties, providing the rationale to deplete mutant p53 as a strategy for cancer therapy. By performing high-throughput screening using ~9,000 compounds, we have identified a drug that specifically triggers degradation of p53 mutants, but has little effect on wild-type p53. Given that mutations in the p53 gene are found only in tumors in most cases, this drug could be used for molecular targeted therapy for a wide range of cancers.
６月にStockholmであるｐ５３の学会（The 16th International p53 workshop）に出席後に、研究打ち合せ他のために来日されます。多くの方の参加を歓迎致します。
共 催：福岡医学会
問合せ：九州大学大学院 医学研究院 基礎放射線医学分野 續 輝久（内線６１４１）
